Neoadjuvant Hypofractionated Chemoradiotherapy for Elderly Rectal Cancer Patients
Author Information
Author(s): Kim Jae Seung, Lee Jaram, Park Hyeung-min, Lee Soo Young, Kim Chang Hyun, Kim Hyeong Rok, Gobert Alain P.
Primary Institution: Department of Surgery, Chonnam National University Hwasun Hospital and Medical School, Hwasun, Republic of Korea
Hypothesis
This study aimed to assess the efficacy of neoadjuvant hypofractionated chemoradiotherapy (HCRT) in elderly patients with locally advanced mid-to-low rectal cancer.
Conclusion
Neoadjuvant HCRT demonstrated reduced radiotherapy-related complications and acceptable long-term oncologic outcomes, making it a viable alternative for elderly patients with rectal cancer.
Supporting Evidence
- Neoadjuvant HCRT resulted in significantly fewer complications compared to LCRT.
- The HCRT group had a higher proportion of patients with an ASA score of 3 or 4.
- Three-year relapse-free survival rates were comparable among treatment groups.
Takeaway
This study looked at how a special type of cancer treatment works for older people with rectal cancer. It found that this treatment can be safer and still help them live longer.
Methodology
A retrospective review of patients diagnosed with locally advanced rectal cancer from January 2013 to December 2020, including those aged 70 years or older, categorized into treatment groups.
Potential Biases
Patient selection was at the discretion of attending surgeons and oncologists, which may have influenced treatment allocation.
Limitations
The study's retrospective design may introduce selection bias, and the small sample size limits the generalizability of the findings.
Participant Demographics
Patients aged 70 years or older with locally advanced rectal cancer.
Statistical Information
P-Value
p = 0.002
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website